Effectiveness of DAA Treatment for HCV in Patients With HCC Effectiveness of DAA Treatment for HCV in Patients With HCC
Is virologic reponse to direct-acting antivirals as robust in HCV patients with hepatocellular carcinoma as in those without?Alimentary Pharmacology &Therapeutics
Publication date: Available online 6 April 2020Source: Journal of Geriatric OncologyAuthor(s): Sukeshi Patel Arora, Snegha Ananth, Norma Ketchum, Jonathan Gelfond, Joel Michalek, Devalingam Mahalingam
Conclusion Semi-quantitative F-18 FDG PET parameters (SUVmax, MTV and T/L) were found to be significantly correlated with Fuhrman grade in patients with RCC and are important markers for differentiation between low- and high-grade tumors. Furthermore, forced diuresis had no incremental value in characterization of primary RCC lesions.
Conclusions: The association of sorafenib does not prolong survival nor delay progression in patients treated with radioembolization. Liver toxicity does not differ among the two therapeutic schemes.
ConclusionsUsing both in vitro and in vivo approaches, we described the profound role of theADAMTSL3 andPTEN genes. This study indicates novel candidate targets for use in HCC treatment and therapy.
Purpose of review The available vaccine and therapies against hepatitis B virus (HBV) rarely eliminate chronic infection with the virus. High mortality resulting from complicating cirrhosis and hepatocellular carcinoma makes improving anti-HBV therapy an important priority. Recent advances with using gene therapy to counter HBV have potential and are the focus of this review. Recent findings The stable replication-competent HBV intermediate comprising covalently closed circular DNA (cccDNA) is the template for expression of all viral genes. Inactivating cccDNA has thus been a focus of research aimed at achieving cure ...
This article is protected by copyright. All rights reserved
Hepatocellular carcinoma (HCC) constitutes 0.5% of childhood malignancies and exhibits poor prognosis. Complete tumor extirpation either by partial liver resection (LR) or liver transplantation (LT) is the only curative treatment. Due to the poor initial outcomes of LT, LR has remained the mainstay of treatment for all but select children fulfilling the Milan criteria (originally designed for adults).